Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
Blood. 2012 May 24; 119(21):5030-6
Chaidos A, Patterson S, Szydlo R, Chaudhry MS, ..., Goldman J, Roberts I, Apperley J, Karadimitris A. Chaidos A, Patterson S, Szydlo R, Chaudhry MS, Dazzi F, Kanfer E, McDonald D, Marin D, Milojkovic D, Pavlu J, Davis J, Rahemtulla A, Rezvani K, Goldman J, Roberts I, Apperley J, Karadimitris A. Blood. 2012 May 24; 119(21):5030-6
The recent article by Chaidos et al. looks at the association between the incidence of acute graft versus host disease (GVHD) in recipients following matched allogenic/sibling transplantation and the cellular dose of immunocompetent cells in the peripheral blood stem cell (PBSC) graft. The results reveal that the dose of a relatively...
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.Subscribe for $9.95/month
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.Recommend to your Librarian
If you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.Request an Institutional Trial
your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.
If you think you should be able to access this content, please contact us.